<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02344355</url>
  </required_header>
  <id_info>
    <org_study_id>201504786</org_study_id>
    <nct_id>NCT02344355</nct_id>
  </id_info>
  <brief_title>A Phase 2 Trial of High-Dose Ascorbate in Glioblastoma Multiforme</brief_title>
  <official_title>Pharmacological Ascorbate Combined With Radiation and Temozolomide in Glioblastoma Multiforme: A Phase 2 Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bryan Allen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Holden Comprehensive Cancer Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Iowa</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This clinical trial evaluates adding high-dose ascorbate (vitamin C) to standard of care
      treatment of glioblastoma multiforme (a type of brain tumor) in adults. All subjects will
      receive high-dose ascorbate in addition to the standard treatment.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Standard treatment for glioblastoma multiforme (GBM) involves maximum safe surgical resection
      followed by radiation combined with temozolomide (a chemotherapy pill you take by mouth).
      After radiation, patients receive additional cycles of temozolomide (adjuvant chemotherapy).

      Participants will:

        -  receive high doses of intravenous (IV) ascorbate three times a week during the combined
           radiation and chemotherapy phase

        -  receive high doses of intravenous (IV) ascorbate twice a week during adjuvant
           chemotherapy (after radiation)

        -  complete health-related quality of life questionnaires pre-radiation, 4 weeks into
           radiation, 4 weeks after radiation, and then every 3 months. In addition, patients will
           complete neurocognitive testing pre-radiation, 4 weeks into radiation, 4 weeks after
           radiation, and approximately 9 months after initiating radiation therapy.

      The adjuvant chemotherapy portion of this study lasts for 6 months. After that is completed,
      participants will go back to standard therapy for their cancer. Participants will continue to
      have life-long follow-up for this study.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 13, 2017</start_date>
  <completion_date type="Anticipated">December 2023</completion_date>
  <primary_completion_date type="Anticipated">April 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>monthly up to 5 years post treatment</time_frame>
    <description>From radiation day 1 until date of death from any cause.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival (PFS)</measure>
    <time_frame>monthly up to 5 years post treatment</time_frame>
    <description>From radiation day 1 to documented disease progression in MRI imaging as described by the RANO criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse Event Frequency</measure>
    <time_frame>monthly through 7 months post-radiation</time_frame>
    <description>Categorize and quantify using the Common Terminology Criteria for Adverse Events (CTCAE) v. 4 from radiation day 1 through 7 months post-radiation.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Health-related Quality of Life (HRQOL)</measure>
    <time_frame>monthly for 3 months, then every 3 months up to 5 years post treatment</time_frame>
    <description>Measure health-related outcomes using the validated EORTC (European Organization for Research and Treatment of Cancer) questionnaires QLQ-C30 and BN-20.</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Glioblastoma Multiforme</condition>
  <arm_group>
    <arm_group_label>ascorbate, radiation, temozolomide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Concomitant therapy:
Radiation therapy, oral temozolomide, and pharmacological ascorbate (ascorbic acid) infusions
Adjuvant therapy:
Oral temozolomide and pharmacological ascorbate (ascorbic acid) infusions</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Temozolomide</intervention_name>
    <description>oral temozolomide (75 mg/m2), given 7 days per week, for a maximum of 49 days during radiation therapy.
Starting 1 month after radiation therapy, additional temozolomide will be given as chemotherapy cycles. Each cycle is 28 days.
For the first cycle, temozolomide will be administered (150 mg/m2) once per day for 5 days.
If the subject tolerates the first cycle well, temozolomide will be prescribed at 200 mg/m2 for cycles 2 through 6. Each cycle is 28 days.</description>
    <arm_group_label>ascorbate, radiation, temozolomide</arm_group_label>
    <other_name>Temodar</other_name>
    <other_name>Temodal</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>radiation therapy</intervention_name>
    <description>Conformal radiation administered daily, M-F, to a total dose of 61.2 Gray in 34 fractions.</description>
    <arm_group_label>ascorbate, radiation, temozolomide</arm_group_label>
    <other_name>EBRT</other_name>
    <other_name>XRT</other_name>
    <other_name>external beam radiation therapy</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ascorbic Acid</intervention_name>
    <description>Intravenous infusions of 87.5g of ascorbate administered three times weekly during radiation.
After radiation, ascorbate is administered twice weekly through the end of cycle 6 of temozolomide.</description>
    <arm_group_label>ascorbate, radiation, temozolomide</arm_group_label>
    <other_name>Vitamin C</other_name>
    <other_name>Ascorbate</other_name>
    <other_name>Pharmacological Ascorbate</other_name>
    <other_name>67457-118-50</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Ability to understand and willingness to sign informed consent (power of attorney
             and/or legally authorized representatives cannot sign on behalf of the patient)

          -  Patients must have newly diagnosed (i.e., within 5 weeks), histologically or
             cytologically confirmed glioblastoma multiforme.

          -  Diagnosis must be made by surgical biopsy or excision.

          -  Therapy must begin ≤ 5 weeks after surgery or biopsy

          -  Age ≥ 18 years

          -  ECOG performance status 0-2. (KPS &gt; 50)

          -  Absolute neutrophil count (ANC) ≥ 1500 cells per mm3

          -  Platelets ≥ 100,000 per mm3

          -  Hemoglobin ≥ 8 g/dL

          -  Creatinine ≤ 2.0 mg

          -  Total bilirubin ≤ 1.5 mg/dL

          -  ALT ≤ 3 times the institutional upper limit of normal

          -  AST ≤ 3 times the institutional upper limit of normal

          -  Tolerate one test dose (15g) of ascorbate.

          -  Not pregnant.

        Exclusion Criteria:

          -  Recurrent high grade glioma

          -  G6PD (glucose-6-phosphate dehydrogenase) deficiency.

          -  Patients actively receiving insulin or using a finger-stick glucometer daily for blood
             glucose measurements

          -  History of allergic reactions attributed to compounds of similar chemical or biologic
             composition to temozolomide.

          -  Significant co-morbid central nervous system disease, including but not limited to,
             multiple sclerosis.

          -  Patients who are on the following drugs and cannot have a drug substitution: warfarin,
             flecainide, methadone, amphetamines, quinidine, and chlorpropamide.

          -  Known active concurrent malignancy, as determined by treating physicians.

          -  Patients who have received prior chemotherapy (including Gliadel wafers) for the
             current glioma.

          -  Prior radiation therapy to the head or neck resulting in overlap of RT fields.

          -  Patients receiving any other investigational agents (imaging agents are acceptable)

          -  Uncontrolled intercurrent illness including, but not limited to, ongoing or active
             infection that would result in a hospital stay or delay of treatment, symptomatic
             congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric
             illness/social situations that would limit compliance with study requirements or
             impact patient safety.

          -  Pregnant women.

          -  Breastfeeding women.

          -  Known HIV-positive individuals. High-dose ascorbate acid is a known CYP450 3A4
             inducer, which results in lower serum levels of antiretroviral drugs.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bryan G. Allen, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Assistant Professor, Department of Radiation Oncology, The University of Iowa</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Bryan G. Allen, MD, PhD</last_name>
    <phone>319-353-8836</phone>
    <email>bryan-allen@uiowa.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Joseph J Cullen, MD</last_name>
    <phone>319-356-1616</phone>
    <email>joseph-cullen@uiowa.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Holden Comprehensive Cancer Center</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52242</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sandy Vollstedt, RN, BSN</last_name>
      <phone>319-353-7143</phone>
      <email>sandy-vollstedt@uiowa.edu</email>
    </contact>
    <contact_backup>
      <last_name>Heather Brown, RN, BAN</last_name>
      <phone>319-384-7912</phone>
      <email>heather-brown@uiowa.edu</email>
    </contact_backup>
    <investigator>
      <last_name>John M. Buatti, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Joseph J. Cullen, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Daniel Berg, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Matthew Howard, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jeremy Greenlee, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>David Hasan, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Patrick Hitchon, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Varun Monga, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Mark C. Smith, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Carryn M. Anderson, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Wenqing Sun, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Douglas Spitz, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Mohammed Milhem, MBBA</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Garry R. Buettner, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Schoenfeld JD, Sibenaller ZA, Mapuskar KA, Wagner BA, Cramer-Morales KL, Furqan M, Sandhu S, Carlisle TL, Smith MC, Abu Hejleh T, Berg DJ, Zhang J, Keech J, Parekh KR, Bhatia S, Monga V, Bodeker KL, Ahmann L, Vollstedt S, Brown H, Shanahan Kauffman EP, Schall ME, Hohl RJ, Clamon GH, Greenlee JD, Howard MA, Schultz MK, Smith BJ, Riley DP, Domann FE, Cullen JJ, Buettner GR, Buatti JM, Spitz DR, Allen BG. O(2)(⋅-) and H(2)O(2)-Mediated Disruption of Fe Metabolism Causes the Differential Susceptibility of NSCLC and GBM Cancer Cells to Pharmacological Ascorbate. Cancer Cell. 2017 Apr 10;31(4):487-500.e8. doi: 10.1016/j.ccell.2017.02.018. Epub 2017 Mar 30. Erratum in: Cancer Cell. 2017 Aug 14;32(2):268.</citation>
    <PMID>28366679</PMID>
  </reference>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 16, 2015</study_first_submitted>
  <study_first_submitted_qc>January 16, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 22, 2015</study_first_posted>
  <last_update_submitted>May 24, 2018</last_update_submitted>
  <last_update_submitted_qc>May 24, 2018</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 28, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of Iowa</investigator_affiliation>
    <investigator_full_name>Bryan Allen</investigator_full_name>
    <investigator_title>Assistant Professor, Radiation Oncology</investigator_title>
  </responsible_party>
  <keyword>Ascorbic Acid</keyword>
  <keyword>temozolomide</keyword>
  <keyword>radiation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glioblastoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Temozolomide</mesh_term>
    <mesh_term>Dacarbazine</mesh_term>
    <mesh_term>Ascorbic Acid</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Data will be released publicly as per participant consent and IRB approval. Individual researchers should contact the research team for data sharing.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

